American Renal Associates (NYSE:ARA) – Stock analysts at Leerink Swann reduced their Q2 2018 earnings estimates for American Renal Associates in a research report issued on Wednesday, May 9th, according to Zacks Investment Research. Leerink Swann analyst A. Gupte now forecasts that the company will post earnings of $0.16 per share for the quarter, down from their prior estimate of $0.17. Leerink Swann has a “Market Perform” rating and a $22.00 price target on the stock.
American Renal Associates (NYSE:ARA) last issued its quarterly earnings results on Tuesday, May 8th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. American Renal Associates had a return on equity of 16.88% and a net margin of 0.60%. The firm had revenue of $194.67 million for the quarter, compared to the consensus estimate of $189.10 million. During the same period in the prior year, the business posted $0.07 earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis.
Shares of American Renal Associates opened at $15.21 on Friday, according to MarketBeat.com. The company has a market capitalization of $513.49 million, a PE ratio of 24.73, a price-to-earnings-growth ratio of 0.77 and a beta of 2.10. American Renal Associates has a fifty-two week low of $15.18 and a fifty-two week high of $15.68. The company has a current ratio of 1.15, a quick ratio of 1.10 and a debt-to-equity ratio of 4.63.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Element Capital Management LLC purchased a new position in American Renal Associates during the 1st quarter worth $263,000. Barclays PLC increased its holdings in American Renal Associates by 23.9% during the 1st quarter. Barclays PLC now owns 52,295 shares of the company’s stock worth $986,000 after purchasing an additional 10,093 shares during the period. A.R.T. Advisors LLC purchased a new position in American Renal Associates during the 1st quarter worth $354,000. OppenheimerFunds Inc. purchased a new position in American Renal Associates during the 1st quarter worth $5,270,000. Finally, Dimensional Fund Advisors LP boosted its position in American Renal Associates by 96.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 255,166 shares of the company’s stock valued at $4,810,000 after acquiring an additional 125,561 shares in the last quarter. Institutional investors own 91.50% of the company’s stock.
About American Renal Associates
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.